Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.
暂无分享,去创建一个
Jianjun Yu | Yumin Dai | Janet Sim | Kevin Shannon | J. Yu | K. Shannon | Jianjun Yu | J. Holash | Jocelyn Holash | Pablo D Garcia | T. Zavorotinskaya | Yumin Dai | Jing Lu | Tatiana Zavorotinskaya | Xiao-Hong Niu | Joseph Castillo | Yingyun Wang | John L Langowski | J. Sim | Yingyun Wang | J. Langowski | Jing Lu | Pablo D. Garcia | Joseph Castillo | Xiaohong Niu
[1] Carmen Blanco-Aparicio,et al. The PIM Family of Serine/Threonine Kinases in Cancer , 2014, Medicinal research reviews.
[2] A. Ferguson,et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. , 2012, Bioorganic & medicinal chemistry letters.
[3] R. Greil,et al. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target , 2012, Journal of Molecular Medicine.
[4] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[5] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[6] F. Giles,et al. The PIM kinases in hematological cancers , 2012, Expert review of hematology.
[7] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[8] J. Martinez-Climent,et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. , 2011, Blood.
[9] Varsha Gandhi,et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. , 2011, Blood.
[10] I. Endo,et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.
[11] A. Kraft,et al. The Pim protein kinases regulate energy metabolism and cell growth , 2010, Proceedings of the National Academy of Sciences.
[12] V. Danilenko,et al. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. , 2010, Current medicinal chemistry.
[13] M. Milella,et al. The mTOR pathway: a new target in cancer therapy. , 2010, Current cancer drug targets.
[14] Stefan Knapp,et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.
[15] Ying-Wei Lin,et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. , 2010, Blood.
[16] Chin-Lee Wu,et al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. , 2009, Cancer research.
[17] J. Gong,et al. Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell. , 2009, The Journal of surgical research.
[18] D. Sabatini,et al. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.
[19] A. Kraft,et al. PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells , 2009, Cancer biology & therapy.
[20] B. Manning,et al. A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.
[21] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[22] T. Tsuruo,et al. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. , 2008, Cancer research.
[23] Toni Cathomen,et al. Zinc-finger Nucleases: The Next Generation Emerges. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] S. Korsmeyer,et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. , 2008, Blood.
[25] N. Magnuson,et al. Pim-1 Kinase-Dependent Phosphorylation of p21Cip1/WAF1 Regulates Its Stability and Cellular Localization in H1299 Cells , 2007, Molecular Cancer Research.
[26] Timothy J. Griffin,et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.
[27] B. Werneburg,et al. Pim kinase substrate identification and specificity. , 2006, Journal of biochemistry.
[28] J. Lawrence,et al. Activation of Mammalian Target of Rapamycin (mTOR) by Insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1* , 2006, Journal of Biological Chemistry.
[29] J. Shabanowitz,et al. mTOR‐dependent stimulation of the association of eIF4G and eIF3 by insulin , 2006, The EMBO journal.
[30] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[31] S. Knapp,et al. Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.
[32] P. Hammerman,et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.
[33] E. Raymond,et al. mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] P. Ekman,et al. Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancer , 2004, The Prostate.
[35] H. Bessler,et al. Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.
[36] J. Blenis,et al. mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E , 2004, Molecular and Cellular Biology.
[37] A. Kraft,et al. The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.
[38] K. Inoki,et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.
[39] Wenyi Wei,et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. , 2002, Biochimica et biophysica acta.
[40] Tian Xu,et al. Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.
[41] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[42] J. Blenis,et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.
[43] M. Gold,et al. CD40 Signaling in B Cells Regulates the Expression of the Pim-1 Kinase Via the NF-κB Pathway1 , 2002, The Journal of Immunology.
[44] P. Koskinen,et al. Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells , 1999 .
[45] A. Berns,et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.
[46] Wim Quint,et al. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.
[47] M. Nawijn,et al. For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.
[48] K. Inoki,et al. TSC2: filling the GAP in the mTOR signaling pathway. , 2004, Trends in biochemical sciences.
[49] M. Gold,et al. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. , 2002, Journal of immunology.
[50] P. Koskinen,et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. , 1999, Blood.
[51] A. Berns,et al. Transgenic mice as a means to study synergism between oncogenes , 1989, International journal of cancer. Supplement = Journal international du cancer. Supplement.